MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 526659 | Name: BMS-189453

Description:

WARNING: This product is for research use only, not for human or veterinary use.

BMS-189453, also known as BMS453, is a potent and selective RARβ agonist and a potent testicular toxin. In Sprague Dawley rats at daily oral doses of 15, 60, or 240 mg/kg for 1 month, BMS-189453 produced increases in leukocyte counts, alkaline phosphatase and alanine aminotransferase levels, and marked testicular degeneration and atrophy at all doses.

Chemical Structure

BMS-189453
BMS-189453
CAS# 166977-43-1

Theoretical Analysis

MedKoo Cat#: 526659

Name: BMS-189453

CAS#: 166977-43-1

Chemical Formula: C27H24O2

Exact Mass: 380.1776

Molecular Weight: 380.49

Elemental Analysis: C, 85.23; H, 6.36; O, 8.41

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
BMS-189453; BMS189453; BMS189453; BMS453; BMS-453; BMS 453.
IUPAC/Chemical Name
E)-4-[2-(5,6-Dihydro-5,5-dimethyl-8-phenyl-2-naphthalenyl)ethenyl]-benzoic acid
InChi Key
VUODRPPTYLBGFM-CMDGGOBGSA-N
InChi Code
InChI=1S/C27H24O2/c1-27(2)17-16-23(21-6-4-3-5-7-21)24-18-20(12-15-25(24)27)9-8-19-10-13-22(14-11-19)26(28)29/h3-16,18H,17H2,1-2H3,(H,28,29)/b9-8+
SMILES Code
O=C(O)C1=CC=C(/C=C/C2=CC=C3C(C)(C)CC=C(C4=CC=CC=C4)C3=C2)C=C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 380.49 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Zdrojewicz Z, Konieczny R, Papier P, Szten F. Brdt Bromodomains Inhibitors and Other Modern Means of Male Contraception. Adv Clin Exp Med. 2015 Jul-Aug;24(4):705-14. doi: 10.17219/acem/33827. Review. PubMed PMID: 26469117. 2: Nya-Ngatchou JJ, Amory JK. New approaches to male non-hormonal contraception. Contraception. 2013 Mar;87(3):296-9. doi: 10.1016/j.contraception.2012.08.016. Epub 2012 Sep 17. Review. PubMed PMID: 22995542; PubMed Central PMCID: PMC3529759. 3: Chung SS, Wang X, Roberts SS, Griffey SM, Reczek PR, Wolgemuth DJ. Oral administration of a retinoic Acid receptor antagonist reversibly inhibits spermatogenesis in mice. Endocrinology. 2011 Jun;152(6):2492-502. doi: 10.1210/en.2010-0941. Epub 2011 Apr 19. PubMed PMID: 21505053; PubMed Central PMCID: PMC3100616. 4: Cipollone D, Cozzi DA, Businaro R, Marino B. Congenital diaphragmatic hernia after exposure to a triple retinoic acid antagonist during pregnancy. J Cardiovasc Med (Hagerstown). 2010 Nov 23. [Epub ahead of print] PubMed PMID: 21107276. 5: Zhang Q, Jiang J, Han P, Yuan Q, Zhang J, Zhang X, Xu Y, Cao H, Meng Q, Chen L, Tian T, Wang X, Li P, Hescheler J, Ji G, Ma Y. Direct differentiation of atrial and ventricular myocytes from human embryonic stem cells by alternating retinoid signals. Cell Res. 2011 Apr;21(4):579-87. doi: 10.1038/cr.2010.163. Epub 2010 Nov 23. PubMed PMID: 21102549; PubMed Central PMCID: PMC3203651. 6: Amati F, Diano L, Campagnolo L, Vecchione L, Cipollone D, Bueno S, Prosperini G, Desideri A, Siracusa G, Chillemi G, Marino B, Novelli G. Hif1α down-regulation is associated with transposition of great arteries in mice treated with a retinoic acid antagonist. BMC Genomics. 2010 Sep 16;11:497. doi: 10.1186/1471-2164-11-497. PubMed PMID: 20846364; PubMed Central PMCID: PMC2996993. 7: Cipollone D, Carsetti R, Tagliani A, Rosado MM, Borgiani P, Novelli G, D'Amati G, Fumagalli L, Marino B, Businaro R. Folic acid and methionine in the prevention of teratogen-induced congenital defects in mice. Cardiovasc Pathol. 2009 Mar-Apr;18(2):100-9. doi: 10.1016/j.carpath.2008.02.007. Epub 2008 Apr 15. PubMed PMID: 18417366. 8: Johnson CS, Zucker RM, Hunter ES 3rd, Sulik KK. Perturbation of retinoic acid (RA)-mediated limb development suggests a role for diminished RA signaling in the teratogenesis of ethanol. Birth Defects Res A Clin Mol Teratol. 2007 Sep;79(9):631-41. PubMed PMID: 17676605. 9: Cipollone D, Amati F, Carsetti R, Placidi S, Biancolella M, D'Amati G, Novelli G, Siracusa G, Marino B. A multiple retinoic acid antagonist induces conotruncal anomalies, including transposition of the great arteries, in mice. Cardiovasc Pathol. 2006 Jul-Aug;15(4):194-202. PubMed PMID: 16844550. 10: Keegan BR, Feldman JL, Begemann G, Ingham PW, Yelon D. Retinoic acid signaling restricts the cardiac progenitor pool. Science. 2005 Jan 14;307(5707):247-9. PubMed PMID: 15653502. 11: Suzuki A, Ito T, Imai E, Yamato M, Iwatani H, Kawachi H, Hori M. Retinoids regulate the repairing process of the podocytes in puromycin aminonucleoside-induced nephrotic rats. J Am Soc Nephrol. 2003 Apr;14(4):981-91. PubMed PMID: 12660332. 12: Beehler BC, Hei YJ, Chen S, Lupisella JA, Ostrowski J, Starrett JE, Tortolani D, Tramposch KM, Reczek PR. Inhibition of disease progression by a novel retinoid antagonist in animal models of arthritis. J Rheumatol. 2003 Feb;30(2):355-63. PubMed PMID: 12563696. 13: Schulze GE, Clay RJ, Mezza LE, Bregman CL, Buroker RA, Frantz JD. BMS-189453, a novel retinoid receptor antagonist, is a potent testicular toxin. Toxicol Sci. 2001 Feb;59(2):297-308. PubMed PMID: 11158723.